National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Ovarian Cancer Prevention (PDQ®)
Patient VersionHealth Professional VersionLast Modified: 06/30/2009



Purpose of This PDQ Summary






Summary of Evidence







Significance






Evidence of Benefit






Get More Information From NCI






Changes to This Summary (06/30/2009)






Questions or Comments About This Summary






More Information



Page Options
Print This Page  Print This Page
Print This Document  Print Entire Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Quit Smoking Today
NCI Highlights
Office of Biorepositories and Biospecimen Research

The Nation's Investment in Cancer Research FY 2010

Report to Nation Finds Declines in Cancer Incidence, Death Rates
Significance

Incidence and Mortality



Incidence and Mortality

The lifetime risk of ovarian cancer is 1.48% with an annual incidence approaching 57.3 per 100,000 women aged 75 to 79 years.[1] In 2009, it is estimated that 21,550 new cases of ovarian cancer will be diagnosed and 14,600 deaths due to ovarian cancer will occur.[2] Incidence rates, but not mortality rates, have been decreasing since 1987.[1]

For the general population of women, the lifetime risk of developing ovarian cancer is 1.48%; the lifetime risk of dying from ovarian cancer is 1.05%.[1] Some women are at an increased risk due to an inherited susceptibility to ovarian cancer with the magnitude of that risk depending on the affected gene and specific mutation. Underlying ovarian cancer risk can be assessed through accurate pedigrees and/or genetic markers of risk. Because of uncertainties about cancer risks associated with specific gene mutations, genetic information may be difficult to interpret outside of families with a high incidence of ovarian cancer. Three inherited ovarian cancer susceptibility syndromes have been described: (1) familial site-specific ovarian cancer; (2) familial breast/ovarian cancer; and (3) Lynch II syndrome, which is a combination of breast, ovarian, endometrial, gastrointestinal, and genitourinary cancers.[3,4] Considering family history in the absence of specific information on BRCA1/2 mutation status, unaffected women who have two or three relatives with ovarian cancer have a cumulative ovarian cancer risk of about 7%.[3,5] Women who have a mother or sister with ovarian cancer have a cumulative lifetime risk of ovarian cancer of about 5%.

This summary does not address the groups that are at high risk due to inherited genetic factors. (Refer to the PDQ summary on the Genetics of Breast and Ovarian Cancer for more information.)

References

  1. Ries LAG, Eisner MP, Kosary CL, et al., eds.: SEER Cancer Statistics Review, 1975-2002. Bethesda, Md: National Cancer Institute, 2005. Also available online. Last accessed October 7, 2009. 

  2. American Cancer Society.: Cancer Facts and Figures 2009. Atlanta, Ga: American Cancer Society, 2009. Also available online. Last accessed September 8, 2009. 

  3. Trimble EL, Karlan BY, Lagasse LD, et al.: Diagnosing the correct ovarian cancer syndrome. Obstet Gynecol 78 (6): 1023-6, 1991.  [PUBMED Abstract]

  4. Genetic risk and screening techniques for epithelial ovarian cancer. ACOG Committee Opinion: Committee on Gynecologic Practice. Number 117--December 1992. Int J Gynaecol Obstet 41 (3): 321-3, 1993.  [PUBMED Abstract]

  5. Kerlikowske K, Brown JS, Grady DG: Should women with familial ovarian cancer undergo prophylactic oophorectomy? Obstet Gynecol 80 (4): 700-7, 1992.  [PUBMED Abstract]

Back to TopBack to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov